Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
Penny Stocks To Buy Today? 4 To Watch Now
02:18pm, Tuesday, 31'st Oct 2023
Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
11:00am, Tuesday, 05'th Sep 2023
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Communications Officer Will Robert
G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates
08:57am, Wednesday, 02'nd Aug 2023
G1 Therapeutics (GTHX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to loss of $0.92 per share a year ago.
G1 Therapeutics to Participate in Two August Investor Conferences
02:30pm, Monday, 31'st Jul 2023
RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August invest
G1 Therapeutics: Without Cash, The CRC Failure Becomes A Tougher Hurdle
07:20pm, Friday, 19'th May 2023
GTHX halted the CRC trial on low survival benefits. There are reasons its other trials with trilaciclib could be more positive.
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
09:07am, Wednesday, 03'rd May 2023
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $1.15 per share a year ago.
G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
12:45pm, Wednesday, 26'th Apr 2023
RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financi
G1 Therapeutics (GTHX) Moves to Buy: Rationale Behind the Upgrade
01:42pm, Wednesday, 12'th Apr 2023
G1 Therapeutics (GTHX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
7 Analysts Have This to Say About G1 Therapeutics
07:00pm, Thursday, 02'nd Mar 2023 Benzinga
Over the past 3 months, 7 analysts have published their opinion on G1 Therapeutics (NASDAQ:GTHX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
12:55pm, Wednesday, 01'st Mar 2023 Zacks Investment Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
11:30am, Wednesday, 01'st Mar 2023 GlobeNewswire Inc.
- Achieved $31.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million -
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
09:02am, Wednesday, 01'st Mar 2023
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
07:10pm, Tuesday, 28'th Feb 2023 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G
G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
03:00pm, Wednesday, 22'nd Feb 2023 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corpor
G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
10:00am, Wednesday, 22'nd Feb 2023
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporat
